Agile Therapeutics Inc
AGRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.43M
Close$
$1.28
15.5% downside
Current Fair Value
15.5% downsideOvervalued by 15.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.43 Million |
|---|---|
| Enterprise Value | $7.87 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-6.71 |
| Beta | 1.58 |
| Outstanding Shares | 6,856,229 |
Return
| Return on Equity | 72.37% |
|---|---|
| Return on Assets | -105.97% |
| Return on Invested Capital | 120.84% |
Valuation & Multiples
| P/E Ratio | -0.23 |
|---|---|
| PEG | -0.11 |
| Price to Sales | 0.5 |
| Price to Book Ratio | -0.38 |
| Enterprise Value to Revenue | 0.36 |
| Enterprise Value to EBIT | -0.58 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | -0.01 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Agile Therapeutics Inc
CEO: Alfred Altomari